JNJ

JNJ

JNJ

Letters With This Ticker

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Keywords/Themes	Theme Commentary	Pitches	Letter
2024 Q3	Sep 30, 2024	Orbis International Equity	-	-	ABBV, GMAB DC, JNJ, NVO, REGN, ROG SW	-			View
2025 Q2	Jul 22, 2025	Miller Howard Investments Income-Equity Strategies	3.8%	-	ABLV, C, CAG, CSCO, EMN, EPD, GS, JNJ, JPM, MRK, PAYX, RHI, STT, TRP	cash flow, dividends, income, total returns, volatility	The letter emphasizes equity income as a durable return driver in an environment of elevated uncertainty, market concentration, and volatile macro signals. Management argues that dividends provide a more stable and predictable component of total returns than buybacks, particularly during downturns when capital discipline matters most. The strategy favors companies with resilient cash flows, balance sheet strength, and a demonstrated commitment to growing shareholder payouts over time.		View
2025 Q2	Jun 30, 2025	Mar Vista US Quality Select	-	12.4%	AAPL, AVGO, JNJ, MSFT, ORCL	free cash flow, Governance, long-term, Quality, volatility	The commentary highlights quality as the dominant driver of long-term returns, particularly in an environment of elevated valuation dispersion. Management stresses consistent free cash flow generation, conservative capital allocation, and strong governance as key defenses against macro uncertainty. Volatility is framed as an opportunity to accumulate superior businesses rather than a signal to rotate styles.	AAPL ORCL AVGO MSFT	View
2025 Q2	Jun 30, 2025	Mar Vista US Quality Select	-	14.3%	AAPL, AVGO, JNJ, META, MSFT, MTD	Balance Sheets, Compounding, Discipline, moats, Quality	The letter emphasizes owning a concentrated portfolio of high-quality U.S. businesses with durable competitive advantages, strong balance sheets, and long reinvestment runways. Management argues that recent volatility has not impaired intrinsic value and instead offers opportunities to add to long-term compounders at more reasonable prices. The outlook remains focused on downside resilience and steady compounding rather than short-term macro forecasting.	GE JNJ MTD AAPL META MSFT AVGO	View
2024 Q2	Jun 30, 2024	Andrew Hill Investment Advisors, Inc.	-	-	AAPL, AMZN, ISRG, JNJ, LLY, MSFT, NVDA	-			View
2024 Q1	Apr 15, 2024	Mayar Capital	7.7%	9.6%	005930 KS, 0K85 LN, 3M, BFAM, BLND LN, CAP FP, GOOG, HLCL LN, HOME SM, HWDN LN, JNJ, KVUE, PYPL, RITN GR, SAP, UL, UPS, VTY LN, VWS DC, WIX	-			View
2023 Q1	Apr 14, 2023	WestEnd Capital	4.9%	4.9%	AMD, CSCO, DIS, GOOG, JNJ, META, NVDA	Artificial Intelligence, Bank Stress, Cost Cutting, Liquidity Expansion, Profitability Bias	The letter analyzes regional bank failures as isolated mismanagement events rather than systemic risk, citing strong Tier 1 capital ratios and concentrated Federal Reserve liquidity support :contentReference[oaicite:0]{index=0}. WestEnd highlights a profitability bias in markets, with mega-cap technology driving returns, and frames cost cutting as a core earnings lever for 2023. Generative artificial intelligence is positioned as a transformative force capable of materially boosting productivity and corporate profits.	GOOGL NVDA AMD	View
2025 Q1	Mar 31, 2025	Mar Vistas U.S. Quality Select	-4.5%	-4.5%	AAPL, AVGO, GOOG, JNJ, NVDA, PEP, TDG, V	-			View
2025 Q1	Mar 31, 2025	Mar Vistas U.S. Quality	-3.1%	-3.1%	AVGO, BRK/A, CRM, JNJ, MSFT, NVDA, PEP, V	-			View
2025 Q1	Mar 31, 2025	Miller Howard Investments Income-Equity Strategies	-	-	ABLV, GILD, HST, JNJ, MPLX, ORI, RHI	-			View
2025 Q1	Mar 31, 2025	American Century Equity Income Fund	4.7%	4.7%	BRK/A, EPD, JNJ, MDT, PM, TROW	-			View
2025 Q1	Mar 31, 2025	Baird Small/Mid Cap Growth Equity Fund	-10.6%	-10.6%	1953345D LN, BWXT, FOUR, JNJ	-			View
2025 Q1	Mar 26, 2025	Andrew Hill Investment Advisors, Inc.	-	-	AAPL, AMZN, DUK, GRMN, JNJ, JPM, MSFT, NFLX, PGR	-			View
2025 Q4	Feb 11, 2026	Tweedy, Browne Value Fund	4.8%	21.6%	005930.KS, BRK-A, CNHI, CVS.L, DHLG.DE, ENVB, FDX, GOOGL, HEIA.AS, IONS, JNJ, NESN.SW, NVST.SW, PRU.L, RMS.PA, ROG.SW, SAF.PA, TTE, U11.SI, WFC	defense, global, healthcare, industrials, international, Pharmaceuticals, technology, value	Health care holdings including pharmaceutical and biotechnology companies added meaningfully to returns. Holdings such as Roche, Novartis, and Ionis Pharmaceuticals benefited from new drug approvals, steady and growing earnings, and business models that continue to generate cash through a wide range of economic conditions. The fund continues to focus on financially sound enterprises purchased at attractive valuations where company stock prices are more than collateralized by underlying intrinsic value. The gap in valuation between US and non-US equities remains quite significant and should serve the fund well going forward. Defense-related holdings such as BAE Systems and Rheinmetall had been standout performers for much of the year but fell back in the 4th Quarter. While these businesses currently benefit from secular growth in defense spending around the world, share prices have moved ahead of underlying fundamentals.		View
2019 Q4	Dec 31, 2019	Aquamarine Fund	-	24.6%	AAPL, AIG, AMZN, BAM, BRK/A, JNJ, KKR, TOO, TSLA, WE	-			View
2025 Q3	Oct 24, 2025	Meridian Hedged Equity Fund	1.6%	-	DHI, FIGR, ICE, JNJ, KVUE, LBRDK	AI, Covered Calls, downside protection, interest rates, Quality	The fund combines unhedged quality longs with a systematic covered-call overlay to dampen volatility and protect downside while still participating in upside. Management sees AI enthusiasm, policy easing, and softening labor trends as key market drivers, but stresses valuation discipline and risk management. Positioning remained ~38% unhedged with the balance in covered calls to balance growth and protection.	JNJ DHI ICE KVUE LBRDK JNJ DHI ICE KVUE LBRDK	View
2025 Q3	Oct 19, 2025	Miller Howard Investments Income-Equity Strategies	3.6%	-	ABBV, BK, C, CAG, CMCSA, COP, ELS, EMN, GSK, HRL, JNJ, ORI, PAYX, TTE, TXN	AI, cash flow, dividends, financials, value	Income-Equity portfolios outperformed on dividend strength from financials and healthcare while contrasting AI-driven spending by large-cap tech firms. The strategy emphasizes high and growing income from undervalued cash-generative companies, avoiding speculative AI capex cycles.	TTE HRL ELS COP	View
2025 Q3	Oct 19, 2025	American Century Equity Income Fund	5.3%	-	AMT, CRH, GOOG, JNJ, KVUE, NSC, PCAR	AI, Consumer Staples, dividends, Health Care, infrastructure	AI investments and data center expansion supported utilities and industrials, contributing to portfolio strength. The fund emphasized quality dividend payers in consumer staples and health care as defensive plays amid inflation and policy uncertainty. Infrastructure demand from AI computing and transportation consolidation also provided tailwinds.		View
2025 Q4	Jan 26, 2026	Impax US Sustainable Economy Fund	4.2%	16.0%	AAPL, AMD, AMZN, AVGO, CLX, CPB, GIS, GOOG, GOOGL, JNJ, LLY, MA, META, MRK, MSFT, NVDA, ORCL, PLTR, STT, V, ZTS	AI, Esg, healthcare, large cap, Pharmaceuticals, semiconductors, sustainability, technology	AI-related companies experienced volatility due to concerns over elevated capital expenditures and returns on large-scale data center investments. Advanced Micro Devices surged on strong demand for AI-optimized chips and data center processors, benefiting from partnerships with hyperscale cloud providers and record GPU sales for AI workloads. Eli Lilly announced a significant agreement with the Trump administration for extended coverage of GLP-1 weight loss drugs within Medicare and Medicaid programs. This created substantial new market opportunities and alleviated concerns about stringent drug pricing. Health Care sector rallied following Trump administration agreements with major pharmaceutical firms to reduce Medicaid drug prices. Companies like Eli Lilly, Merck, and others benefited from robust sales growth, positive clinical trial results, and improved market access for key medications. The portfolio's sustainability tools were key performance drivers, with industry tilts from the Sustainability Lens and Corporate Resilience profiles both benefiting returns. Companies with higher Corporate Resilience scores outperformed while those with poor scores like Meta and Palantir were excluded and underperformed.		View
2025 Q4	Jan 24, 2026	Miller Howard Investments	-	-	AAPL, AMZN, BAC, BRK-B, GOOG, GOOGL, JNJ, JPM, META, MSFT, NVDA, PG, TSLA, WMT, XOM	Concentration, dividends, Indices, Magnificent 7, nuclear, SMRs, value	The US is on the cusp of a nuclear renaissance driven by rising electricity demand, policy support, and emerging technologies like small modular reactors. Nuclear capacity could quadruple by 2050, though regulatory, economic, and execution risks remain significant challenges. Miller/Howard maintains strict dividend focus across portfolios, avoiding Magnificent 7 stocks in income-oriented strategies. The firm emphasizes high current income and growth of income as core differentiators in an increasingly concentrated market. Index reconstitutions have compromised style integrity by adding growth-oriented Magnificent 7 stocks to value indices. This creates concentration risk and challenges traditional value investing principles based on lower valuations and higher dividend yields.		View
2025 Q4	Jan 24, 2026	Miller Howard Investments Income-Equity Strategies	15.6%	15.6%	ABBV, C, COP, CSCO, EMN, ETR, GILD, GPS, GSK, HRB, HRL, JEF, JNJ, JPM, MPLX, MTB, PAYX, RF, STT, VICI, VZ	AI, dividends, income, productivity, value	AI represents a transformative technology that could drive step-change improvements in economic productivity. The manager believes AI's greatest impact will come from companies using it as an input to improve operations rather than those selling AI products. Many dividend-paying companies in labor-intensive industries could benefit significantly from AI adoption through process automation and efficiency gains. The portfolio focuses on high dividend yields approximately 3x the S&P 500, with strong dividend coverage ratios and projected dividend growth. Six companies increased dividends in the quarter, led by MPLX with a 13% increase. The strategy emphasizes collecting high and rising dividends while compounding real cash returns through disciplined reinvestment. The portfolio trades at significant discounts to the broad market, with P/E ratios 40-42% below the S&P 500. The manager believes many steady-growing companies are overlooked by markets focused on AI winners, creating opportunities in businesses with lower assumed margins and productivity that could benefit from AI adoption.		View
2025 Q4	Jan 23, 2026	American Century Equity Income Fund	1.8%	11.9%	BDX, EPD, GOOGL, JNJ, JPM, MCD, MCHP, MDLZ, MDT, MMC, MU, NSC, PEP, PNC, RHHBY, SYY, TFC, UL	Consumer Staples, dividends, financials, healthcare, Quality, value	The fund continues to focus on higher-quality companies with stable revenues and profits, low indebtedness, resilient cash flows and predictable business models that are less sensitive to economic conditions. This approach is viewed as offering resilience amid continuing inflation and uncertain macroeconomic conditions. Healthcare led all sectors in the fourth quarter after being beaten down for much of the year. The fund remains keen on healthcare stocks, particularly those in the healthcare equipment and supplies industry, because they are attractively valued and demand tends to be less susceptible to changes in the economic environment. The fund's investment objective focuses on current income and long-term capital growth, with a strategy of investing in companies believed to be undervalued. The portfolio positioning emphasizes income generation through dividend-paying stocks and preferred securities.		View
2025 Q4	Jan 20, 2026	Madison Dividend Income Fund	-0.2%	8.3%	AAPL, AMZN, AVGO, BLK, CME, CVX, GOOGL, HON, JNJ, MDT, META, MS, MSFT, NEE, NVDA, TSLA, UNP, XOM	defensives, dividends, income, large cap, Quality, value	The fund focuses on high-quality, above-average dividend yield stocks with sustainable competitive advantages. Portfolio holdings increased dividends by 6% on average over the past year, well above inflation rates. The fund's absolute portfolio dividend yield of 2.53% compares favorably to 1.12% for the S&P 500. Many dividend paying companies are historically cheap compared to the broad market. The relative yield of the Dividend Income Fund was 2.25x the S&P 500 at year-end, at the very high end of historical ranges. The equal weight S&P 500 is trading at just half the valuation level of the S&P 500. The fund maintains a high-quality portfolio with strong balance sheets that could protect on the downside in a market correction. 94% of fund holdings are rated A- or better by Standard & Poor's, which compares favorably to the S&P 500 at 35% and the Russell 1000 Value at 22%.		View
2025 Q4	Jan 20, 2026	Harding Loevner Global Equity	1.9%	12.7%	0700.HK, 1299.HK, 2308.TW, 300124.SZ, 300760.SZ, 4519.T, 6758.T, 6861.T, ABBV, ACN, ADBE, ALFA.ST, AME, AMZN, APH, ASML, ATCO-A.ST, ATD.TO, ATKR, AVGO, BKNG, CME, COMP.L, CSGP, D05.SI, DE, DHR, DPLM.L, EFX, ELV, EPI-A.ST, FN, GMAB, GOOGL, HDFCBANK.NS, HEI, HLN.L, HON, JNJ, META, MSFT, NFLX, NOC, NVDA, PGR, ROG.SW, SAP, SGSN.SW, SHEL, SLB, SU.PA, TMO, TSM, TTD, TW, V, VRTX, WMMVY	AI, global, international, semiconductors, technology, value	AI represents a capital-expenditure regime with two distinct camps: hyperscalers investing in computing capacity and physical enablers of the buildout. The US market is more dependent on AI continuing to surprise to the upside due to richer valuations and concentrated exposure. Global semiconductor ecosystem enables AI buildout, spanning chip foundries, memory-chip makers, and equipment manufacturers. International markets are more heavily tilted toward this manufacturing and infrastructure provider segment. International markets trade at roughly half the multiples of US stocks, offering more attractive valuations. Non-US markets start from cheaper valuations and possess more diverse growth opportunities unrelated to AI.	GOOG	View
2025 Q4	Jan 18, 2026	Distillate Capital Fundamental Stability & Value	0.0%	0.0%	BMY, CAH, CSCO, ELV, FFIV, FI, GPS, HCA, JBHT, JNJ, LOW, MO, MPC, MRK, REGN, TDC, TEL, TMUS, UBER, VST	free cash flow, fundamentals, international, Quality, rebalancing, small caps, valuation, value	The firm emphasizes systematic value investing through their proprietary free cash flow valuation methodology. They focus on stocks trading at attractive valuations while avoiding richly valued names, with their U.S. FSV strategy trading at more than double the free cash flow yield of the S&P 500. The strategy systematically rotates out of names that have increased in value and reinvests into less expensive stocks. The firm filters for high quality companies with stable cash flows and low debt levels. Their investment process excludes negative free cash flow companies and avoids those with high amounts of leverage while seeking fundamental stability. This quality focus has historically been smart but was a drag on returns in 2025 as unprofitable stocks outperformed significantly. The firm sees significant opportunity in small and mid-sized U.S. stocks, though selectivity is critical given the large number of unprofitable and heavily-indebted companies. Their small/mid strategy filters out negative free cash flow companies and high leverage names. The S&P 600 excludes many troubled names and has considerably outperformed the Russell 2000 over time.		View
2025 Q4	Jan 18, 2026	Distillate Capital Small/Mid Cap Quality & Value	0.0%	0.0%	BMY, CAH, CSCO, ELV, FFIV, FI, GPS, HCA, JBHT, JNJ, LOW, MO, MPC, MRK, REGN, TDC, TEL, TMUS, UBER, VST	free cash flow, fundamentals, Quality, rebalancing, small cap, valuation, value	The letter extensively discusses valuation concerns across markets, highlighting that U.S. equities are historically expensive and trading at levels typically associated with subdued future returns. The firm's strategies focus on finding attractively valued stocks where quality and value overlap, with their portfolios trading at significant discounts to benchmarks. Quality is a core focus of the firm's investment process, emphasizing cash flow stability and avoiding highly leveraged or unprofitable companies. The letter discusses how their strategies systematically filter out negative free cash flow companies and those with high debt levels while seeking fundamental stability. The letter identifies significant opportunities in small and mid-sized U.S. stocks, noting that avoiding high debt levels and money-losing businesses has historically been smart but was a drag on returns in 2025. The firm sees this as creating attractive entry points for quality small cap investing.		View
2025 Q4	Jan 18, 2026	Distillate Capital Large Cap Value	0.0%	8.6%	000660.KS, 005930.KS, BMY, CAH, CSCO, ELV, FFIV, FI, HCA, JBHT, JNJ, LOW, MO, MPC, MRK, REGN, TEL, TMUS, UBER, VST	FCF, fundamentals, international, Quality, rebalancing, small caps, valuation, value	U.S. equities are historically expensive by any measure and at levels typically associated with subdued future returns. The S&P 500 is trading near record multiples with just 20 stocks accounting for over 50% of the market at a 120% premium to the rest. Historical analysis shows that rich starting valuations correlate with lower longer-term returns. Despite rich overall market valuations, many high quality stocks remain attractively valued. The firm's large cap strategy trades at a free cash flow yield more than double the S&P 500 and 60% above Russell 1000 Value. Value stocks significantly outperformed after the 2000 tech bubble when similar valuation disparities existed. Significant opportunities exist in smaller stocks where avoiding high debt levels and money-losing businesses has historically been smart but was an enormous drag on returns in 2025. Negative free cash flow stocks comprised 35% of Russell 2000 and rose 67% on average, demonstrating unusual market conditions.		View
2025 Q4	Jan 18, 2026	Mayar Capital	4.5%	14.1%	005930.KS, 7476.T, 7974.T, BFAM, BKNG, BNNTF, CAP.PA, CFR.SW, CRDA.L, GOOGL, JNJ, KVUE, NESN.SW, NKE, OR.PA, PYPL, SOLV, TW.L, UL, UPS, V, VWS.CO	defense, fundamentals, global, Quality, Speculation, value	The fund maintains its disciplined value investing approach, focusing on boring companies with durable competitive advantages trading at reasonable prices. The manager emphasizes that fundamentals eventually win out despite current market speculation. The manager identifies significant red flags in circular financing fueling the AI boom, comparing it to vendor financing of the late 90s. Companies like Oracle, OpenAI, Nvidia and CoreWeave participate in arrangements that effectively fund their own customers' purchases. Strategy Inc. (formerly MicroStrategy) serves as a cautionary tale of speculative excess. The stock fell 60% as its premium to Bitcoin holdings evaporated, forcing the company to sell equity to cover preferred dividends rather than buy more Bitcoin.	NKE TW LN BKNG	View
2025 Q4	Jan 15, 2026	Columbia Dividend Opportunity Fund	2.8%	15.9%	ABBV, ALB, BAC, BLK, BRX, C, CSCO, DRI, GOOGL, GPC, GPS, GS, HD, IBM, IP, JNJ, JPM, LUV, MCD, MO, MRK, MU, PM, QRVO, SBUX, SWKS, T, UDR, XOM	AI, Banking, dividends, financials, Lithium, technology, value, Yield	The fund focuses on companies with historically consistent and increasing dividends, though dividend stocks generally underperformed during the quarter as investors favored speculative companies over defensive characteristics. The manager maintains a positive view on dividend-paying stocks as an out-of-favor segment largely devoid of speculative activity. The market remained supported by ongoing enthusiasm about the artificial intelligence theme, though there was a brief stretch of concern in November about a possible AI bubble. The manager sees potential for improved relative performance if excitement surrounding AI begins to cool. The quarter was characterized by broadening market leadership away from mega-cap technology companies, contributing to relative strength in the value style. The fund's investment universe offers fundamentally sound companies trading with attractive yields and reasonable valuations. A new position in mandatory convertible securities of lithium producer Albermarle made a sizable contribution as lithium prices rose due to reduced supply from China, and market participants became more optimistic about the metal's potential use in energy storage applications.		View
2025 Q4	Jan 13, 2026	Mar Vista US Quality Select	0.2%	12.8%	AAPL, AMZN, APH, AVGO, CRM, DHR, EFX, GOOG, JNJ, LIN, META, MSFT, NFLX, NVDA, ORCL, ROP, SAP, TSM, V	AI, Cloud, growth, large cap, Quality, semiconductors, Streaming, technology	The structural shift driven by Artificial Intelligence is transitioning from proof-of-concept to demonstrable return on investment. Early monetization is visible in advertising, cloud computing, and semiconductors. Companies deploying AI infrastructure are seeing tangible improvements in ROIC through more efficient ad targeting and premium AI cloud services. Cloud computing continues to be a key beneficiary of AI infrastructure deployment. Google Cloud emerged as a standout performer with 34% revenue growth and $155 billion backlog. Microsoft's Azure platform remains capacity-constrained with accelerating growth and increasing adoption of Copilot offerings. Taiwan Semiconductor represents the dominant manufacturer for leading fabless chip designers including NVIDIA, Apple, and Broadcom. The global arms race to develop artificial general intelligence will support multiple years of robust growth for foundries with leading-edge capabilities. Netflix has built a durable economic moat around its globally-scaled streaming business. With more than 300 million members, Netflix enjoys the lowest content cost per subscriber in the industry, enabling it to profitably outspend rivals and accelerate its competitive flywheel.		View
2024 Q1	Jul 22, 2024	Qualivian Investment Partners	2.4%	15.3%	AMZN, JNJ, META, NOC, ORLY, SPGI, WSO	-			View
2023 Q1	Apr 22, 2023	Mayar Capital	7.7%	9.6%	9627 JP, BFAM, BNR GR, CFR SJ, DAN SW, DBX, EA, HLCL LN, HOME SM, HWDN LN, JNJ, PYPL, RITN GR, UN SW, WIX LN	-			View
2025 Q1	Mar 31, 2025	Mayar Capital	2.9%	2.9%	005930 KS, AHT LN, ALO FP, BFAM, BLND LN, CAP FP, FOUR LN, GOOG, HLCL LN, JNJ, KVUE, LH, NKE, NVO, PYPL, SAP FP, SOLV, SOM LN, UPS, V, VTY LN	-			View
2023 Q1	Mar 31, 2023	ClearBridge Investments Dividend Strategy	0.0%	0.0%	AAPL, BAC, JNJ, MET, MSFT, PFE, SAP, USB	-			View

Pitches With This Ticker

Date	Pitch Type	Author	Company	Industry	Sub Industry	Bull / Bear	Stock Exchange	Keywords	Action
Feb 20, 2026	Seeking Alpha	Seeking Alpha	Johnson & Johnson	Healthcare	Pharmaceuticals	Bull	New York Stock Exchange	capital allocation, Dividend Growth, inventory management, investment thesis, Johnson & Johnson, legal developments, P/E ratio, pharmaceuticals, risk profile, Valuation premium	View Pitch
Feb 2, 2026	Seeking Alpha	Seeking Alpha	Johnson & Johnson	Healthcare	Pharmaceuticals	Bull	New York Stock Exchange	biopharma, growth products, healthcare, Immunology, innovation, large-cap, Oncology, pipeline, revenue guidance	View Pitch
Jan 28, 2026	Fund Letters	Kevin Toney	Johnson & Johnson	Health Care	Pharmaceuticals	Bull	New York Stock Exchange	dividends, earnings, healthcare, Quality, spin-off	View Pitch
Jan 27, 2026	Fund Letters	Silas Myers	Johnson & Johnson	Health Care	Pharmaceuticals	Bull	New York Stock Exchange	Defensiveness, Generics, Medtech, pharma, pipeline	View Pitch
Jan 20, 2026	Fund Letters	Charles K. Bobrinskoy	Johnson & Johnson	Health Care	Pharmaceuticals	Bull	New York Stock Exchange	biopharma, drug pipeline, earnings growth, healthcare innovation, pharmaceuticals	View Pitch
Jan 8, 2026	Fund Letters	Silas Myers	Johnson & Johnson	Health Care	Pharmaceuticals	Bull	New York Stock Exchange	healthcare, litigation, pharmaceuticals, Regulatory risk, Talc	View Pitch
Nov 29, 2025	Fund Letters	Clayton Freeman	Johnson & Johnson	Health Care	Pharmaceuticals	Bull	NYSE	dividends, Immunology, litigation, Loe, Oncology, pipeline	View Pitch
Nov 29, 2025	Fund Letters	Clayton Freeman	Johnson & Johnson	Health Care	Pharmaceuticals	Bull	NYSE	dividends, Immunology, litigation, Loe, Oncology, pipeline	View Pitch
Aug 7, 2025	Seeking Alpha	Edmund Ingham	Johnson & Johnson	Health Care	Drug Manufacturers - General	Neutral	NYSE	—	View Pitch

BSD Shareholders of JNJ

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025

Manager Name	Fund Name	Fund AUM	Invested Value	Portfolio Weight	Shares Owned	Shares Bought / Sold During Quarter	% Bought / Sold During Quarter	% of Shares Outstanding Owned
No investor data available.

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

Follow Us On: